AUA 2022: Whitmore Lecture
AUA 2022 Whitmore Lecture, what happened to continent urinary diversion in bladder cancer? urinary diversion in bladder cancer,
Related Articles
PSMA-Targeted Radionuclide Therapy in the Pre- and Post-Chemotherapy Settings in Prostate Cancer – Louise Emmett
In a conversation with Phillip Koo, Louise Emmett unpacks the complexities of PSMA-targeted diagnostics and treatments in prostate cancer. They explore the significance of key…
Prostate Cancer Cell Metabolism Dictates Differentiation and Therapy Response – Andrew Goldstein
Andrea Miyahira hosts Andrew Goldstein to discuss his group’s research on prostate cancer, published in Nature Cell Biology. Dr. Goldstein, along with his team, including…
PARP Inhibitor Monotherapy for Prostate Cancer Patients
PARP inhibitor monotherapy in prostate cancer, genomic landscape of prostate cancer, advanced prostate cancer, metastatic castrate-resistant prostate cancer (mCRPC), homologous recombination repair (HRR)-deficient tumors, BRCA1/2-mutated…
Sexual Structure Sparing for Prostate Cancer Radiotherapy: A Systematic Review – Beyond the Abstract
Sexual Structure Sparing for Prostate Cancer Radiotherapy, Prostate Cancer, Sexual Structure Sparing, intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), QUANTEC review, PCa RT…
Epidemiological Trends and Treatment Innovations in Advanced Prostate Cancer: An In-Depth Analysis of the AUA’s Amended 2023 Guidelines, Journal Club – Rashid Sayyid & Zachary Klaassen
Rashid Sayyid and Zach Klaassen review the 2023 amended AUA guidelines on advanced prostate cancer. They focus on the epidemiology, early evaluation, and patient counseling.…
Discussion Between Expert Clinicians and Patients on the ProtecT Trial, A Journal Club for Patients with Prostate Cancer – Matthew Cooperberg
In this Prostate Cancer Patient Journal Club discussion, Matthew Cooperberg and Jenny Donovan address quality-of-life outcomes from the ProtecT trial’s surveillance group. Jenny notes that…
Imaging Response to PSMA Radiopharmaceutical Therapy “Presentation” – Jeremie Calais
At the 2024 UCSF-UCLA PSMA Conference, Jeremie Calais highlights the advanced diagnostic capabilities of PSMA PET/SPECT in monitoring responses to PSMA-targeted radiopharmaceutical therapy, showcasing its…
Highlighting APCCC 2024: An International Prostate Cancer Meeting – Silke Gillessen & Aurelius Omlin
Alicia Morgans hosts a discussion with Professors Silke Gillessen and Aurelius Omlin about the upcoming APCCC 2024, emphasizing its significance for the prostate cancer community.…
The Efficacy and Resistance-Breaking Potential of EPI-7386 Masofaniten in Castration-Resistant Prostate Cancer – Andrew Laccetti
Zach Klaassen engages Andrew Laccetti in a discussion about Masofaniten (EPI-7386), a pioneering anti-androgen therapy targeting the N-terminal domain of the androgen receptor, aimed at…
State of the Art and Future Challenges of Urethra-Sparing Stereotactic Body Radiotherapy for Prostate Cancer: A Systematic Review of Literature – Beyond the Abstract
Prostate cancer, stereotactic body radiotherapy (SBRT), Urethra-Sparing Stereotactic Body Radiotherapy, Urethra-Sparing Stereotactic Body Radiotherapy for Prostate Cancer, magnetic resonance guided radiotherapy (MRgRT).